In a lecture at the "Genomics in Cancer Risk Assessment" workshop in 2009, Hans Lehrach of the Max Planck Institute for Molecular Genetics stated that, "Life is the translation of the information in the genome into the pheno type of the organism. The organism 'computes' this phenotype from its genotype, given a spe cific environment." The goal of human risk assessment is to decide whether a given level of exposure to a particular chemical or substance is acceptable to human health and to provide risk management measures based on an evalua tion and prediction of the effects of that expo sure on human health. Within this framework, the current safety paradigm for assessing pos sible carcinogenic properties of drugs, cosmet ics, industrial chemicals, and environmental exposures relies mainly on in vitro genotoxicity testing followed by 2year bioassays in mice and rats. This testing paradigm was developed 40-50 years ago with the initial premise that "mutagens are also carcinogens" (Ames 1973) and that the carcinogenic risk to humans can be extrapolated from the tumor incidence in rodents after lifetime exposure to maximally tol erated doses of chemicals (Weisburger 1983) .
Genotoxicity testing is used as a surro gate for carcinogenicity testing and is required for initiation of clinical trials (Jacobs and JacobsonKram 2004) and for most safety assessments of industrial chemicals. Although the carcinogenicitytesting paradigm has effectively protected patients and consumers from the introduction of harmful carcinogens as drugs and other products, the testing para digm is clearly not sustainable in the future. The causal link between genetic damage and carcinogenicity is well documented; however, the limitations of genotoxicity and carcinoge nicity testing assays, the presence of additional nongenotoxic mechanisms, issues of species specific effects, and the lack of mechanistic insights provide enormous scientific challenges.
The genetic toxicology testing battery has been designed to be highly sensitive in predicting chemical carcinogenicity. The genetic toxicology testing battery detects 93% of carcinogens (Kirkland et al. 2005 (Kirkland et al. , 2006 . However, the extremely high sensitiv ity of the testing paradigm comes at a cost of very low specificity. For instance, 50% of noncarcinogens among pharmaceuticals have some findings in genotoxicity assays (Hoffmann and Hartung 2006; MacDonald 2004; Snyder 2009; Snyder and Green 2001) . Furthermore, the current testing paradigm for carcinogenicity fails to detect a variety of nongenotoxic carcinogens, such as hormone type agents, which may impose a considerable human health risk.
The 2year rodent carcinogenicity bio assays are associated with high costs, high animal burden, a long time frame (often ≥ 3 years), limited accuracy, and the uncer tainty associated with extrapolating from rodents to humans. Additional frustrations exist because of the limited predictability of the 2year bioassay and, in particular, the problem of predicting false positives. For instance, the Carcinogenic Potency Database (Gold 2010) includes results from chronic, longterm animal cancer tests with mice, rats, and hamsters amounting to a total of 6,540 individual experiments with 1,547 chemicals; 751 of those chemicals (51%) have positive findings in rodent studies. Similarly, when one considers all chronically used human pharma ceuticals, some 50% induce tumors in rodents, yet only 20 human pharmaceutical com pounds have been identified as carcinogens in epidemiological studies, despite the fact that quite a large number of epidemiological stud ies have been carried out on these compounds (e.g., nonsteroidal antiinflammatory drugs, benzodiazepines, and phenobarbital). This high incidence of tumors in bioassays has led to questions concerning the human relevance of tumors induced in rodents (Knight et al. 2006; Ward 2008) .
In addition, concerns have been raised regarding the agerelated tumor incidence in the rodent bioassay, with many tumors arising Background: The current safety paradigm for assessing carcinogenic properties of drugs, cosmetics, industrial chemicals, and environmental exposures relies mainly on in vitro genotoxicity testing followed by 2-year rodent bioassays. This testing battery is extremely sensitive but has low specificity. Furthermore, rodent bioassays are associated with high costs, high animal burden, and limited predictive value for human risks. oBjectives: We provide a response to a growing appeal for a paradigm change in human cancer risk assessment. Methods: To facilitate development of a road map for this needed paradigm change in carcinogenicity testing, a workshop titled "Genomics in Cancer Risk Assessment" brought together toxicologists from academia and industry and government regulators and risk assessors from the United States and the European Union. Participants discussed the state-of-the-art in developing alternative testing strategies for carcinogenicity, with emphasis on potential contributions from omics technologies. results and conclusions: The goal of human risk assessment is to decide whether a given exposure to an agent is acceptable to human health and to provide risk management measures based on evaluating and predicting the effects of exposures on human health. Although exciting progress is being made using genomics approaches, a new paradigm that uses these methods and human material when possible would provide mechanistic insights that may inform new predictive approaches (e.g., in vitro assays) and facilitate the development of genomics-derived biomarkers. Regulators appear to be willing to accept such approaches where use is clearly defined, evidence is strong, and approaches are qualified for regulatory use. In summary, dependency on the rodent model as a gold standard of cancer risk assessment neglects the high number of false positives and clearly has serious limitations. Consequently, there is a growing appeal for a paradigm change after "50 years of rats and mice." Recent reports from the National Research Council of the U.S. National Academies have focused on the challenges of toxicology and human risk assessment, appeal ing for dramatic changes to move forward (National Research Council 2007a , 2007b . In addition, the current demands for toxicity and carcinogenicity testing of highvolume chemicals together with limitations of animal use as stipulated by the European Union's Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regu lation (Combes et al. 2006 ) will require revolutionary changes in testing and risk assessment paradigms.
To develop a road map for this needed paradigm change in carcinogenicity test ing, a workshop was held in August 2009 in Venice, Italy, titled "Genomics in Cancer Risk Assessment." This workshop brought together toxicologists from academia and industry and government regulators and risk assessors from the United States and the European Union to discuss the stateoftheart in developing alter native testing strategies for carcino genicity, focusing on contributions from the omics technologies. What follows is a highlight of the major conclusions and suggestions from this workshop as a path forward.
The Challenge: Addressing Human Relevance
Participants concluded, based on both scientific and technical reasons, that the current assays need to be improved if not replaced by mechanismbased assays that would enable assessment of relevance of observed findings for human health and disease. Preferentially, these assays should be derived from human in vitro cellular models and should be properly validated against human in vivo data (com ing from investigations of patients, clinical trials, and human biomarker research) through translational research. New assays optimally should not rely on animal use and should have sufficient throughput that would satisfy demands for testing. Despite an array of cur rently established in vitro and in vivo testing methods, deriving insights into carcinogenic mechanisms with respect to the oncogenic potential of chemicals to humans is a difficult task. One suggestion to improve human can cer risk assessment is to incorporate genomic and genetic approaches into the risk assess ment paradigm (EllingerZiegelbauer et al. 2008a; Guyton et al. 2008) . Because molecular or informational pathways are generally con served across species from yeast to man (Ideker et al. 2001 ) and because pathways are gener ally well represented on all assay platforms, although the actual representation may vary, genomicbased systems biology approaches have the potential to bridge the in vitro and in vivo preclinical assays with humanrelevant cancer mechanisms. Where pathways differ between species, those differences can provide valuable insight in understanding molecular mechanisms responsible for speciesspecific responses to exposures. Remarkable research activity is being conducted in the use of genomics as a tool for toxicological evaluation of chemicals and pharmaceuticals, including genotoxic and nongenotoxic carcinogenicity investigations after both in vitro and in vivo exposures. Several successful demonstrations of limited and welldefined applications of genomic approaches to risk assessment have included the identification of hazards through classification of test or unknown compounds with compounds of a particular class (Hamadeh et al. 2002; van Delft et al. 2004) , the generation of mechanistic infor mation through molecular pathway analysis revealing biological processes effected by expo sures (Amundson et al. 2005; Aubrecht and Caba 2005; Heinloth et al. 2003; Liu et al. 2006) , and the prediction of a limited num ber of specific potential adverse effects from exposures (EllingerZiegelbauer et al. 2005 (EllingerZiegelbauer et al. , 2008b Fielden et al. 2007; Heinloth et al. 2004; van Delft et al. 2004) .
Recent work by Lamb and colleagues integrates gene expression transcriptomics data from human cells with chemical and drug information together with disease information into what the authors refer to as a "Connectivity Map" (Lamb 2007; Lamb et al. 2006) . Applying this approach to sys tems biology, the authors demonstrate their ability to discover the activity of a compound (referred to as a "perturbagen") in a molecu lar pathway that the compound had not pre viously been known to affect. Although this data set was clearly limited, the results were promising. The implication of this study is that a more robust database of information might provide insight into potential risks rele vant to human exposures to a wide variety of chemicals and drugs.
For nongenotoxic chemicals, the impor tant signals for identifying human cancer haz ards may be detected in shorterterm studies using toxicogenomics approaches, rather than routinely relying on data from 2year rodent bioassays. Characteristic pathwayassociated gene expression signatures have been identi fied in the liver and kidneys of rats after short term (2 weeks or 90 days) treatment with carcinogens, which fit very well the known mechanisms of carcinogenesis (Auerbach et al. 2010) . These can discriminate genotoxic and nongenotoxic carcinogens from noncarcino gens, with a typical sensitivity of 0.92 and specificity of 0.88, a significant improvement over the performance of current animalbased models. This may contribute to weightof evidence considerations in cancer risk assess ment. Pathwayassociated gene signatures may serve as biomarkers that may then help to predict a carcinogenic hazard in differ ent organs even after shortterm treatment (EllingerZiegelbauer et al. 2008a) .
Perhaps the ideal approach for assess ing human risk associated with exposure to chemical carcinogens would be an in vitro assay that would apply genomics in con junction with bioinformatics methods to interrogate mechanisms of action of tested compounds. This information would then be used for the development and qualifica tion of genomic biomarkers for chemical carcinogenesis that would provide the basis for mechanismbased risk assessment. In vitro classification of compounds for true genotoxic and nongenotoxic carcinogenicity, using cell lines, including human liver cellular mod els, can be 70-90% accurate (van Delft et al. 2004) . Furthermore, developing a genomic based biomarker approach to identify irrel evant findings, for instance, findings from in vitro chromosome damage assays that are false positives and irrelevant findings for human risk assessment, would have spe cific, immediate human relevance and would provide significant improvement in current genotoxicity testing (Aubrecht and Caba 2005; Goodsaid et al. 2010) . Tissuespecific in vitro approaches to recognize carcinogens need to be developed, and such efforts would focus research appropriately on producing necessary tools to address organ specific ity and ultimately improve prediction and risk assessment (carcinoGENOMICS 2007; Vinken et al. 2008) . Furthermore, high throughput approaches that are currently being evaluated by the U.S. Environmental Protection Agency (EPA) ToxCast effort and by the National Institute of Environmental Health Sciences, National Toxicology Program, the National Human Genome Research Institute, and the U.S. EPA Tox21 highthroughput screening effort have con centrated on a functional genomic approach that would allow triage of compounds for testing. These efforts could thus provide the opportunity to focus limited resources on the most important, problematic compounds (Dix et al. 2007 ).
Gaps to Be Addressed
The ultimate, longterm goal for applying genomicbased approaches to human cancer risk assessment is the eventual replacement of the current testing paradigm, which includes genotoxicity and carcinogenicity testing, with mechanismbased assays that would allow both hazard detection and assessment of the relevance to humans, not rodents, of observed findings. For this to become a reality, molecu lar alterations and mechanistic insight derived from human cellular models need to be correlated with injury or potential for injury in humans. Linking outcomes of toxico genomics investigations in vitro to ongoing human omicsbased biomarker studies could help to make this happen. Consequently, more extensive data that are derived from human studies are needed, in particular, appropriate samples from individuals exposed at low but well defined levels. Because development of biomarkers suitable to monitor exposure in human populations is essential to human risk and relevance, approaches to develop genomic biomarkers for individuals exposed to a specific agent of concern would provide the necessary advances to develop broad biomarkerbased approaches (McHale et al. 2010) . Genomic approaches have the potential to facilitate the discovery of surrogate biomarkers that are gene expression signatures or expression pat terns of proteins or metabolites linked with a particular phenotype. This "phenotypic anchoring" of genomic signatures (Paules 2003) would allow for the use of patterns as surrogate biomarkers that may be useful in treatment and risk assessment decision making in the clinical or regulatory setting, even if the underlying molecular mechanism is not fully understood. This approach has been demon strated powerfully with geneexpression-based surrogate biomarkers that have provided infor mation to clinicians about the prognosis of breast tumors and that have helped in the design of appropriate therapeutic treatment regimes (Paik et al. 2004; Sotiriou and Pusztai 2009; van 't Veer et al. 2002) . Thus, genomic approaches that use appropriate human sam ples from welldesigned studies of exposed human populations may yield powerful novel biomarkers useful both in the clinical setting and in risk assessment.
Systems toxicology approaches should also pay attention to the relative sensitivity of humans and the variability in the human response. As carcinogens are increasingly recognized to affect multiple molecular mechanisms and thus multiple cellular path ways, insights into these mechanisms could inform new predictive approaches, such as predictive in vitro assays, and allow for the development of specific, mechanismbased human biomarkers. These new biomarkers could then provide insight into the genetic variability in responses to the risk of develop ing cancers. The use of such mechanistic data will play a key role in the future of risk assess ment to aid in identification of additional sources of human variability and susceptibility (e.g., background diseases and processes, coex posures) and improve prediction of interac tions across environmental and endogenous exposures. Identifying mechanistic drivers of adverse responses will be particularly impor tant in the risk assessment of exposures at low doses. Once progress is made in these areas, it may be possible to address the dose-response curve in an individual, which can take mul tiple forms, depending on such factors as the individual's genetic background, the target tissue affected, and the actual internal dose of a specific compound or chemical. Linking outcomes of in vitro toxicogenomics inves tigations to ongoing human omicsbased biomarker studies may make this happen. Goodsaid et al (2010) noted that regulators appear to be willing to accept such approaches where use is clearly defined, evidence is strong, and approaches are validated and qualified for regulatory use. In general, educating stake holders is crucial to successfully implement the new testing paradigm.
Toxicogenomics applications require further technological standardization as well as biological standardization, especially with respect to the annotation of genes and pathways related to toxicologically rele vant end points. Further progress must be made in systems toxicology applications, Figure 1 . Road map for human cancer risk assessment. Four major projects that aim to develop a genomic biomarker approach for human cancer risk assessment have been initiated in the United States and the European Union (EU). carcinoGENOMICS (EU's Sixth Framework Programme, funded from 2009 to 2012) attempts to develop human cell-based in vitro models and tools to detect carcinogens. The Phase I and the Phase II studies, conducted by the U.S. EPA (ToxCast program) and the National Institutes of Health (Tox21 program), exploit available biochemical and molecular assays to develop high-throughput, predictive assay panels. The International Life Sciences Institute Health and Environmental Sciences Institute (ILSI HESI) Genotoxicity Working Group (Genotox WG) focuses on developing an in vitro genomic biomarkers that can provide mechanistic context to in vitro genotoxicity testing. The aim of the FDA's Critical Path Initiative Predictive Safety Testing Consortium Carcinogenicity Working Group (PSTC Carcinogenicity WG) is to develop an in vivo genomic biomarker detecting hepatocarcinogenicity, applicable for use in early drug development. These initiatives are expected to yield biomarkers and assays that initially could be applied as weight of evidence in a fit-for-purpose manner. This will provide the time and opportunity for refining the methods and assembling a new testing paradigm. Concurrently, progress in the development of cancer diagnostic methods is expected to provide data specific to human cancer that, after integration with in vitro and preclinical genomics data, will open additional avenues to further increase human relevance of this new testing paradigm. Solid lines indicate current funding activities; dotted lines indicate anticipated continuation of funding or projects into the future. that is, developing integrative approaches across multiple genomic, genetic, molecu lar, and cellular assays to assess toxic events from a holistic perspective, as described with the Connectivity Map approach. The first generation toxicogenomics studies used microarraybased wholegenome analysis of gene expression modifications. Current tech nologies analyze the interplay between epi genetic events (e.g., wholegenome DNA methylation and histone acetylation, modifica tions of levels of mRNA, modifications of lev els of regulatory microRNAs) and proteomic and metabolomic events, thus increasing the potential of identifying pivotal pathways whose perturbation functionally contributes ultimately in inducing toxicity and disease. To accomplish this will require better data analysis tools, specifically bioinformaticsbased decisionsupporting tools, to help not only the research scientists but also chemical and drug registrants and regulators. Furthermore, this will require publically accessible databases that integrate different methods and types of information, from emerging omics data types to traditional pathological, toxicologi cal, physiological, molecular, and clinical data. New methods of training and familiarizing all parties involved with these new tools and strat egies will be needed. This training may require new additions to existing curricula for students and special, targeted training opportunities for professionals.
A major challenge is the need to pheno typically anchor genomic responses from in vitro studies and testing assays on chemical carcinogenesis to human patho physiology. The critical need for human relevancy is not a new problem but a serious issue that has appeared to be intractable in the past, because of, at least in part, the paucity of critical human samples and information. For this to be overcome now, cooperation and data sharing between private and public research partners and broad collaborative efforts will be required.
The Path Forward
Toxicogenomics is considered a very promis ing but complex technology requiring coor dinated planning and execution that is highly transparent and participatory to all segments of toxicology and risk assessment: academia, government, industry, non governmental orga nizations, and the public. Although we are still far from replacing the current testing para digm for cancer risk assessment, toxicogenom ics approaches at their current stage may be used to add weight of evidence to a risk assess ment, by supporting additional studies in the presence or absence of a certain mechanism or mode of action and by describing end points that are not evaluated in a "checklist" manner but through an integrated scientific approach. Much work is needed, but a num ber of activities both in Europe and in the United States are already ongoing that will help address the issue of bringing genomic approaches into human cancer risk assess ment (Figure 1 ). In support of this approach, the U.S. Food and Drug Administration in a joint undertaking with the European Union's European Medicines Agency has already invited the pharmaceutical industry to submit omics data in the context of the registration of novel compounds (Goodsaid et al. 2010) . Importantly, the REACH legislation states:
The Commission, Member States, industry and other stakeholders should continue to contribute to the promotion of alternative test methods on an international and national level including computer supported methodologies, in vitro methodologies, as appropriate, those based on toxicogenomics, and other relevant methodologies. (REACH Online 2006) Regulatory agencies should not simply wait for these future developments but should antici pate that these novel toxicogenomicsbased approaches also require the development of novel quality standards and further regula tory criteria. We feel it is critical to establish a formal global dialogue among regulatory agencies to coordinate and facilitate prog ress and acceptance of anticipated advances (Figure 1 , Regulatory discussions, Phase I and II). In this line, we call upon inter national regulatory agencies and risk assess ment decision makers to establish two phases of regu lar dialogues, each over a 2 or 3year period, that will address initially the imple mentation of genomicsbased assay develop ment and then the use of genomicsbased weightofevidence information in risk assess ment decisions. With the progress being made in science today using genomics approaches, particularly using readily accessible human material, in conjunction with rigorous tradi tional scientific endeavors, we are now at a point when genomic applications in human studies can yield important information for better human cancer risk assessment.
